CAJ | 학술논문

目的：观察注射用核糖核酸II(以下简称：核II)对晚期消化道肿瘤患者的疗效和安全性。方法80例晚期消化道肿瘤患者单盲随机分为核II组和对照组,对照组采用单纯化疗方案,核II组于化疗同时静脉滴注核II 200 mg/d,连续45 d (一个疗程)后检测患者T细胞亚群的变化、外周白细胞变化、毒副不良反应发生率、并通过Karnofsky评分评价患者的生活质量。结果①核II组化疗后CD3、CD4、CD56的阳性率明显高于对照组(P<0.05)。②核II组化疗后的白细胞下降程度、不良反应II度发生比例均明显低于对照组(P<0.05)。③核II组化疗后Karnofsky评分升高比例57.5%明显高于对照组42.5%。结论①核II可刺激T细胞成熟和分化,显著提高机体免疫功能。②核II可减少化疗过程中患者白细胞的下降、毒副反应的发生。③化疗联合核II可以有效改善患者生活质量。
목적：관찰주사용핵당핵산II(이하간칭：핵II)대만기소화도종류환자적료효화안전성。방법80례만기소화도종류환자단맹수궤분위핵II조화대조조,대조조채용단순화료방안,핵II조우화료동시정맥적주핵II 200 mg/d,련속45 d (일개료정)후검측환자T세포아군적변화、외주백세포변화、독부불량반응발생솔、병통과Karnofsky평분평개환자적생활질량。결과①핵II조화료후CD3、CD4、CD56적양성솔명현고우대조조(P<0.05)。②핵II조화료후적백세포하강정도、불량반응II도발생비례균명현저우대조조(P<0.05)。③핵II조화료후Karnofsky평분승고비례57.5%명현고우대조조42.5%。결론①핵II가자격T세포성숙화분화,현저제고궤체면역공능。②핵II가감소화료과정중환자백세포적하강、독부반응적발생。③화료연합핵II가이유효개선환자생활질량。
Objective To observe the efficacy and safety of RNA II for injection in patients with advanced gastrointestinal cancer. Methods 80 patients with advanced gastrointestinal cancer were single-blind randomized into group RNA II and control group. The simple chemotherapy for control group, using RNA II 200 mg/day, 45 days (one course) for the group RNAII on the base of chemotherapy, and then detect the of variation of T-cell subsets, the leukocytes, the incidence of adverse side effects and evaluate the life quality of the patients through the Karnofsky score. Results ①The positive rate of CD3, CD4 , CD56 in group RNAII were higher than the control group (P<0.05).②The decreased level of WBC and the ratio of adverse events in group RNAII were lower than the control group (P<0.05). ③The promotion ratio of Karnofsky score in group RNAII(57.5%) was higher than control group(42.5%). Conclusion ①RNA II can stimulate the maturation of T-cell, improve the immune function of the patients.②RNA II can reduce the decrease of WBC, the side effects of chemotherapy.③RNA II combined with chemotherapy can improve the quality of life effectively.